Diabetes and cardiovascular disease: The potential benefit of incretin-based therapies

Current Atherosclerosis Reports

Volumn 13, Issue 2, 2011, Pages 115-122

  Addison, Daniel ^a   Aguilar, David ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; DPP IV; Glucagon like peptide 1; Incretin hormones cardiovascular disease

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; TASPOGLUTIDE; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HORMONAL REGULATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK REDUCTION;

ADMINISTRATION, ORAL; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; CAUSALITY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCRETINS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 79955897721     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0153-0     Document Type: Review

References (50)

1. Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed September 2010.
2. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290:1884-1890. (Pubitemid 37430605)
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053.
4. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114-126. (Pubitemid 46058619)
5. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115:1544-1550. (Pubitemid 46648639)
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241:2035-2038.
7. Sarwar N, Gao P, Seshasai SR, Gobin R, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375:2215-2222. Results from this meta-analysis of nearly 700,000 people confirm the burden of diabetes to the current era. Diabetes confers a twofold increased risk of CVD, including CAD and ischemic stroke, independent from other conventional risk factors.
8. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010; 33:442-449.
9. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-1809.
10. Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165:1910-1916. (Pubitemid 41352087)
11. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
12. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572. (Pubitemid 351831357)
13. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559. This randomized controlled study of 10,251 diabetic patients tested whether intensive therapy to target normal glycated hemoglobin would reduce cardiovascular events. The study demonstrated that the use of intensive therapy to target normal glucose levels did not significantly reduce major cardiovascular events and suggested possible harm.
14. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:394-403.
15. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370:1129-1136. (Pubitemid 47464583)
16. Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Metaanalysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010; 170:1191-1201.
17. Food and Drug Administration: Guidance for Industry. Diabetes Mellitus-Evaluation Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed September 2010.
18. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34 Suppl 2:S65-S72. This in-depth review discusses the physiology behind the incretin system.
19. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122:S3-S10. This in-depth review discusses the physiology behind the incretin system and the importance of incretin-based therapies in glucose homeostasis.
20. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63:492-498. (Pubitemid 16035703)
21. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157. (Pubitemid 46711096)
22. Vilsboll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45:1111-1119. (Pubitemid 34985287)
23. Egan JM, Bulotta A, Hui H, et al. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003; 19:115-123. (Pubitemid 36417195)
24. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004; 47:806-815. (Pubitemid 38756992)
25. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609-613. (Pubitemid 32195226)
26. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
27. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:217-223. (Pubitemid 46198322)
28. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100. (Pubitemid 40616618)
29. Horton ES, Silberman C, Davis KL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010; 33:1759-1765.
30. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32:84-90.
31. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23:334-339. Results pooled from six trials examining over 2100 patients who were studied for over 6 months reveal that exenatide therapy was associated with a small but significant reduction in systolic blood pressure. The investigators found that the greatest reduction in blood pressure was seen in individuals with systolic blood pressure of at least 150 mm Hg at baseline and in African Americans.
32. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89:3055-3061. (Pubitemid 38766408)
33. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-1215.
34. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59:1030-1037.
35. Liu H, Dear AE, Knudsen LB, et al. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009; 201:59-66.
36. Oeseburg H, de Boer RA, Buikema H, et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010; 30:1407-1414.
37. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33:1607-1609.
38. Fadini GP, de Kreutzenberg S, Agostini C, et al. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009; 207:213-219.
39. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54:146-151. (Pubitemid 40105106)
40. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53:501-510.
41. Noyan-Ashraf MH, Momen MA, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58:975-983. This article examines the role of liraglutide therapy in the modulation of acute myocardial infarction in mice. The results demonstrate a significant reduction in post-ischemic injury and improved myocardial function, leading to improved survival.
42. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965. (Pubitemid 38282847)
43. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829. (Pubitemid 47268274)
44. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3:195-201.
45. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-2252. (Pubitemid 36629873)
46. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289:H2401-2408.
47. Bhashyam S, Fields AV, Patterson B, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010; 3:512-521.
48. Poornima I, Brown SB, Bhashyam S, et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008; 1:153-160. The investigators examined the efficacy of 3 months of GLP-1 infusion therapy in obese hypertensive rats and found that GLP-1 was associated with significant survival benefits. The results also reveal preserved left ventricular mass and function, with decreased myocyte apoptosis.
49. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12:694-699. (Pubitemid 44881367)
50. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117:2340-2350. This important study describes cardioprotective actions of GLP-1 (7-36) mediated through the known GLP-1 receptor. In addition, the study also demonstrates novel cardiac and vascular actions of GLP-1 (7-36) and its metabolite GLP-1 (9-36), independent of the known GLP-1 receptor.